The latest guidelines of the World Health Organization (WHO) on TB treatment, emphasize the importance of digital technologies in supporting the implementation of the End TB Strategy. The guidelines contain the first-ever WHO evidence-based recommendations on the use of phones, video or electronic medication monitors to help patients adhere to TB medication and deliver TB care.
The Member States of the World Health Organization (WHO) elected Dr Tedros Adhanom Ghebreyesus to a five-year term as the new Director-General of the WHO. Dr Tedros is a physician and former Minister of Health and Minister of Foreign Affairs of the Federal Democratic Republic of Ethiopia. The election took place at the Seventieth World Health Assembly in Geneva, Switzerland.
“Dr Tedros is a proven leader who spearheaded massive improvements in Ethiopia’s healthcare system. His work to develop a national cadre of community health workers was a pioneering solution for improving public health that many other countries have since followed,” said José Luis Castro, Executive Director of the International Union Against Tuberculosis and Lung Disease (The Union). “He has the credentials, the diplomatic skills, and the management experience to effectively lead the WHO during one of the most critical moments in its history.”
Read an opinion piece by the Union’s Executive Director, José Luis Castro, on the need for WHO reform
Ethiopia’s former health minister has been elected to serve as the next director-general of the World Health Organization — the first African picked to lead the global health agency. Tedros Adhanom Ghebreyesus will succeed Dr. Margaret Chan on July 1.
WHO Director-General charts progress made in the fight against TB in new report - “Ten years in public health 2007-2017”
WHO today released the chapter on the fight against tuberculosis (TB) in the Director-General’s new report “Ten years in public health 2007-2017”. The report chronicles the evolution of global public health over the decade that Dr. Margaret Chan served as Director-General at WHO.
The chapter highlights the successes and challenges in global efforts to combat TB since 2007, when the fight against TB faced two major crises: a continuing co-epidemic of TB/HIV ravaging Africa and the emergence of more deadly drug resistance strains called XDR-TB or extensively drug-resistant TB. It elaborates the critical role played by WHO and its partners through a culture of innovation, leading to breakthroughs in diagnosis, treatment and the roll-out of a new Strategy to end TB.
The World Health Organization just published the first ever Global Hepatitis Report, which notes that the viral hepatitis mortality rate is increasing worldwide, while deaths caused by HIV and tuberculosis continue to drop.
Who Reports Global Burden of Viral Hepatitis is Increasing
TB and Depression
April 7, 2017
To coincide with World Health Day, the World Health Organization (WHO) published a Newsflash regarding TB and Depression.
The World Health Organization (WHO) today recommended the use in all settings of a next-generation Xpert® MTB/RIF assay (called Xpert® MTB/RIF Ultra) as a replacement for the current Xpert MTB/RIF® cartridge.
New tuberculosis (TB) ethics guidance, launched today by the World Health Organization (WHO), aims to help ensure that countries implementing the End TB Strategy adhere to sound ethical standards to protect the rights of all those affected.
The new WHO ethics guidance addresses contentious issues such as, the isolation of contagious patients, the rights of TB patients in prison, discriminatory policies against migrants affected by TB, among others. It emphasizes five key ethical obligations for governments, health workers, care providers, nongovernmental organizations, researchers and other stakeholders to:
Ethics Guidance for the Implementation of the End TB Strategy
Fact Sheet on Ethical Issues in TB Prevention, Treatment and Care
Johns Hopkins University and the Medicines Patient Pool (MPP) have signed a license agreement to facilitate the clinical development of the tuberculosis drug, sutezolid. Sutezolid, an oxazolidinone antibiotic in the same class as linezolid, has shown promise in use as a compound in early stage trials to be more potent and less toxic in the treatment of TB.